|
|
Article: Inhibitex Reports Third Quarter 2009 Financial Results.
- Article from:
- Business Wire
- Article date:
- November 6, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Recent $23 Million Financing Supports Operations through 2011
ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX), today announced its financial results for the third quarter ended September 30, 2009. The Company held cash, cash equivalents and short-term investments of $21.1 million at September 30, 2009, as compared to $33.1 million at December 31, 2008.
"We continue to make progress on all fronts, including the advancement of our differentiated antiviral development programs and most recently, the completion of a financing that we believe strategically positions us to develop both FV-100 and INX-189 through their respective clinical proof of concept trials," ...